Literature DB >> 28824851

Myeloid leukemia switch as immune escape from CD19 chimeric antigen receptor (CAR) therapy.

Fabiana Perna1, Michel Sadelain1.   

Abstract

Entities:  

Year:  2016        PMID： 28824851      PMCID： PMC5558892          DOI： 10.21037/tcr.2016.08.15

Source DB:  PubMed          Journal:  Transl Cancer Res        ISSN： 2218-676X            Impact factor:   1.241


× No keyword cloud information.
  40 in total

1.  CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia.

Authors:  S S Kenderian; M Ruella; O Shestova; M Klichinsky; V Aikawa; J J D Morrissette; J Scholler; D Song; D L Porter; M Carroll; C H June; S Gill
Journal:  Leukemia       Date:  2015-02-27       Impact factor: 11.528

Review 2.  The MLL gene and translocations involving chromosomal band 11q23 in acute leukemia.

Authors:  Marc De Braekeleer; Frédéric Morel; Marie-Josée Le Bris; Angèle Herry; Nathalie Douet-Guilbert
Journal:  Anticancer Res       Date:  2005 May-Jun       Impact factor: 2.480

3.  Lineage Switch in MLL-Rearranged Infant Leukemia Following CD19-Directed Therapy.

Authors:  Ahmad Rayes; Richard L McMasters; Maureen M O'Brien
Journal:  Pediatr Blood Cancer       Date:  2016-02-23       Impact factor: 3.167

4.  Targeting of folate receptor β on acute myeloid leukemia blasts with chimeric antigen receptor-expressing T cells.

Authors:  Rachel C Lynn; Mathilde Poussin; Anna Kalota; Yang Feng; Philip S Low; Dimiter S Dimitrov; Daniel J Powell
Journal:  Blood       Date:  2015-04-17       Impact factor: 22.113

5.  Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9.

Authors:  Andrei V Krivtsov; David Twomey; Zhaohui Feng; Matthew C Stubbs; Yingzi Wang; Joerg Faber; Jason E Levine; Jing Wang; William C Hahn; D Gary Gilliland; Todd R Golub; Scott A Armstrong
Journal:  Nature       Date:  2006-07-16       Impact factor: 49.962

Review 6.  CAR therapy: the CD19 paradigm.

Authors:  Michel Sadelain
Journal:  J Clin Invest       Date:  2015-09-01       Impact factor: 14.808

7.  Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia.

Authors:  Quan-shun Wang; Yao Wang; Hai-yan Lv; Qing-wang Han; Hui Fan; Bo Guo; Li-li Wang; Wei-dong Han
Journal:  Mol Ther       Date:  2014-09-01       Impact factor: 11.454

8.  Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells.

Authors:  Saar Gill; Sarah K Tasian; Marco Ruella; Olga Shestova; Yong Li; David L Porter; Martin Carroll; Gwenn Danet-Desnoyers; John Scholler; Stephan A Grupp; Carl H June; Michael Kalos
Journal:  Blood       Date:  2014-03-04       Impact factor: 22.113

9.  Lineage switch at relapse of childhood acute leukemia: a report of four cases.

Authors:  Meerim Park; Kyung Nam Koh; Bo Eun Kim; Ho Joon Im; Seongsoo Jang; Chan-Jeoung Park; Hyun-Sook Chi; Jong Jin Seo
Journal:  J Korean Med Sci       Date:  2011-05-18       Impact factor: 2.153

10.  High-affinity FRβ-specific CAR T cells eradicate AML and normal myeloid lineage without HSC toxicity.

Authors:  R C Lynn; Y Feng; K Schutsky; M Poussin; A Kalota; D S Dimitrov; D J Powell
Journal:  Leukemia       Date:  2016-02-22       Impact factor: 11.528
View more
  12 in total

1.  Integrating Proteomics and Transcriptomics for Systematic Combinatorial Chimeric Antigen Receptor Therapy of AML.

Authors:  Fabiana Perna; Samuel H Berman; Rajesh K Soni; Jorge Mansilla-Soto; Justin Eyquem; Mohamad Hamieh; Ronald C Hendrickson; Cameron W Brennan; Michel Sadelain
Journal:  Cancer Cell       Date:  2017-10-09       Impact factor: 31.743

2.  Universal Chimeric Antigen Receptors for Multiplexed and Logical Control of T Cell Responses.

Authors:  Jang Hwan Cho; James J Collins; Wilson W Wong
Journal:  Cell       Date:  2018-04-26       Impact factor: 41.582

Review 3.  New development in CAR-T cell therapy.

Authors:  Zhenguang Wang; Zhiqiang Wu; Yang Liu; Weidong Han
Journal:  J Hematol Oncol       Date:  2017-02-21       Impact factor: 17.388

4.  c-MYC regulates mRNA translation efficiency and start-site selection in lymphoma.

Authors:  Kamini Singh; Jianan Lin; Yi Zhong; Antonija Burčul; Prathibha Mohan; Man Jiang; Liping Sun; Vladimir Yong-Gonzalez; Agnes Viale; Justin R Cross; Ronald C Hendrickson; Gunnar Rätsch; Zhengqing Ouyang; Hans-Guido Wendel
Journal:  J Exp Med       Date:  2019-05-29       Impact factor: 14.307

5.  CSPG4-Specific CAR T Cells for High-Risk Childhood B Cell Precursor Leukemia.

Authors:  Dennis C Harrer; Gerold Schuler; Jan Dörrie; Niels Schaft
Journal:  Int J Mol Sci       Date:  2019-06-05       Impact factor: 5.923

Review 6.  CSPG4 as Target for CAR-T-Cell Therapy of Various Tumor Entities-Merits and Challenges.

Authors:  Dennis C Harrer; Jan Dörrie; Niels Schaft
Journal:  Int J Mol Sci       Date:  2019-11-26       Impact factor: 5.923

7.  Overcoming leukemia heterogeneity by combining T cell engaging bispecific antibodies.

Authors:  Sayed Shahabuddin Hoseini; Madelyn Espinosa-Cotton; Hong-Fen Guo; Nai-Kong V Cheung
Journal:  J Immunother Cancer       Date:  2020-11       Impact factor: 13.751

8.  Nanobody Based Dual Specific CARs.

Authors:  Stijn De Munter; Joline Ingels; Glenn Goetgeluk; Sarah Bonte; Melissa Pille; Karin Weening; Tessa Kerre; Hinrich Abken; Bart Vandekerckhove
Journal:  Int J Mol Sci       Date:  2018-01-30       Impact factor: 5.923

Review 9.  Mechanisms of Relapse After CD19 CAR T-Cell Therapy for Acute Lymphoblastic Leukemia and Its Prevention and Treatment Strategies.

Authors:  Xinjie Xu; Qihang Sun; Xiaoqian Liang; Zitong Chen; Xiaoli Zhang; Xuan Zhou; Meifang Li; Huilin Tu; Yu Liu; Sanfang Tu; Yuhua Li
Journal:  Front Immunol       Date:  2019-11-12       Impact factor: 7.561

Review 10.  A narrative review of critical factors for better efficacy of CD19 chimeric antigen receptor T cell therapy in the treatment of B cell malignancies.

Authors:  Jia Liu; Luyao Wang; Hongbo Yang; Meng Xing; Shihai Liu; Zhuang Yu; Leina Ma
Journal:  Transl Cancer Res       Date:  2020-09       Impact factor: 1.241
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.